CN111356764B - 降低血清胆固醇和pcsk9的组合物和方法 - Google Patents

降低血清胆固醇和pcsk9的组合物和方法 Download PDF

Info

Publication number
CN111356764B
CN111356764B CN201880074862.5A CN201880074862A CN111356764B CN 111356764 B CN111356764 B CN 111356764B CN 201880074862 A CN201880074862 A CN 201880074862A CN 111356764 B CN111356764 B CN 111356764B
Authority
CN
China
Prior art keywords
inhibitor
cholesterol
akr1a1
ldl
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880074862.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN111356764A (zh
Inventor
J·S·斯坦勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Priority to CN202410548659.4A priority Critical patent/CN118512442A/zh
Publication of CN111356764A publication Critical patent/CN111356764A/zh
Application granted granted Critical
Publication of CN111356764B publication Critical patent/CN111356764B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880074862.5A 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法 Active CN111356764B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410548659.4A CN118512442A (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562784P 2017-09-25 2017-09-25
US62/562,784 2017-09-25
PCT/US2018/052214 WO2019060720A1 (en) 2017-09-25 2018-09-21 COMPOSITIONS AND METHODS FOR REDUCING SERUM CHOLESTEROL AND PCSK9

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410548659.4A Division CN118512442A (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法

Publications (2)

Publication Number Publication Date
CN111356764A CN111356764A (zh) 2020-06-30
CN111356764B true CN111356764B (zh) 2024-05-24

Family

ID=65810650

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880074862.5A Active CN111356764B (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法
CN202410548659.4A Pending CN118512442A (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410548659.4A Pending CN118512442A (zh) 2017-09-25 2018-09-21 降低血清胆固醇和pcsk9的组合物和方法

Country Status (6)

Country Link
US (2) US11576900B2 (https=)
EP (1) EP3688163A4 (https=)
JP (2) JP7414712B2 (https=)
CN (2) CN111356764B (https=)
CA (1) CA3076889A1 (https=)
WO (1) WO2019060720A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111356764B (zh) * 2017-09-25 2024-05-24 卡斯西部储备大学 降低血清胆固醇和pcsk9的组合物和方法
AU2019344066B2 (en) * 2018-09-21 2025-05-29 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
CN113648427B (zh) * 2021-08-20 2023-07-28 山东大学 透明质酸-es2-af肽偶联物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153211A (en) * 1983-09-14 1992-10-06 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
WO2016090373A1 (en) * 2014-12-05 2016-06-09 Case Western Reserve University Compositions and methods of modulating s-nitrosylation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
JPS58140020A (ja) 1982-02-13 1983-08-19 Nippon Zoki Pharmaceut Co Ltd 脂質代謝改善剤
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
WO2002047680A2 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US20020198201A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an aldose reductase inhibitor
EP1431399A1 (en) 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
JP4544503B2 (ja) 2003-04-15 2010-09-15 株式会社アミノアップ化学 雲南苦丁茶成分を含有する組成物
WO2005000229A2 (en) 2003-06-04 2005-01-06 Duke University Compositions and methods for modulating s-nitrosoglutathione reductase
JP2007015924A (ja) 2003-06-12 2007-01-25 Sanwa Kagaku Kenkyusho Co Ltd 抗癌剤耐性を克服する薬剤及びそのスクリーニング方法
US20100292178A1 (en) 2003-07-21 2010-11-18 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
US9308206B2 (en) 2004-08-23 2016-04-12 The Board Of Regents Of The University Of Texas System Compositions and methods for treating colon cancer
US20110092566A1 (en) 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
DK1961420T3 (da) 2005-12-16 2012-08-27 Sanwa Kagaku Kenkyusho Co Middel til forebyggelse og behandling af akut nyresvigt
KR20080108465A (ko) 2006-02-20 2008-12-15 가부시키가이샤산와카가쿠켄큐쇼 뇌졸중에 있어서의 뇌허혈 또는 뇌허혈 재관류 장해의 예방또는 치료제
CA2669887A1 (en) 2006-11-21 2008-05-29 Viamet Pharmaceuticals, Inc. Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties
US8440617B2 (en) 2007-03-22 2013-05-14 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing
WO2010104595A1 (en) 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Methods and compositions for the treatment of metabolic and cardiovascular disorders
EP2295593A1 (en) 2009-09-15 2011-03-16 Philippe Marliere Method for the enymatic production of 3-hydroxy-3-methylbutyric acid from acetone and acetyl-CoA
US20120083501A1 (en) 2010-09-24 2012-04-05 Hunt Kevin W Compounds for treating neurodegenerative diseases
US20150335615A1 (en) * 2013-01-04 2015-11-26 Toshihisa Kawai Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
EP3179995B1 (en) 2014-08-12 2018-11-07 University of Pécs (Pécsi Tudományegyetem) Methods and materials for reducing ischemia-reperfusion injury
US10537557B2 (en) 2016-01-27 2020-01-21 Case Western Reserve University Methods of treating respiratory disorders
CN111356764B (zh) * 2017-09-25 2024-05-24 卡斯西部储备大学 降低血清胆固醇和pcsk9的组合物和方法
AU2019344066B2 (en) * 2018-09-21 2025-05-29 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
US12391703B2 (en) * 2019-09-23 2025-08-19 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153211A (en) * 1983-09-14 1992-10-06 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
WO2016090373A1 (en) * 2014-12-05 2016-06-09 Case Western Reserve University Compositions and methods of modulating s-nitrosylation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.;Tavori H等;《Expert Rev Cardiovasc Ther》;第12卷(第10期);1137-1144 *
Metabolism of gamma hydroxybutyrate in human hepatoma HepG2 cells by the aldo-keto reductase AKR1A1;Alzeer S等;《Biochem Pharmacol》;第92卷(第3期);499-505 *

Also Published As

Publication number Publication date
US20230190710A1 (en) 2023-06-22
US20200268717A1 (en) 2020-08-27
JP2024001162A (ja) 2024-01-09
EP3688163A4 (en) 2022-12-14
CN118512442A (zh) 2024-08-20
CN111356764A (zh) 2020-06-30
JP2020535142A (ja) 2020-12-03
EP3688163A1 (en) 2020-08-05
WO2019060720A1 (en) 2019-03-28
US11576900B2 (en) 2023-02-14
JP7414712B2 (ja) 2024-01-16
CA3076889A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
US20230190710A1 (en) Compositions and methods of reducing serum cholesterol and pcsk9
US10479771B2 (en) Pyridazinone and pyridone compounds
CN101969773B (zh) 用于降低尿酸的化合物和方法
US20230024914A1 (en) Methods of treating respiratory disorders
US12049455B2 (en) Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
TWI458481B (zh) ３－戊基苯乙酸的鹽及其藥學用途
TW200401768A (en) Methods of treatment with CETP inhibitors and antihypertensive agents
JP2022105013A (ja) ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用
WO2003077832A2 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
EP3730509A1 (en) Compound for treating metabolic diseases and preparation method and use thereof
US20050137251A1 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
US20170326148A1 (en) Prevention or treatment of uric acid or gout disease
JP2018516275A (ja) ナフトキノン系化合物を含む、膵炎を治療又は予防する組成物
JP2023506201A (ja) 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用
JP2008538372A (ja) テトラヒドロビオプテリンおよび他の化合物を含んでなる組み合わせ製品
JPH09506068A (ja) 悪液質治療のためのオキソフタラジン類
JP2001294535A (ja) ヘパリンコファクターｉｉの医薬用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant